Mehmet Sitki Copur^*†, Julie Marie Wurdeman^†, Debra Nelson^*, Ryan Ramaekers^*, Dron Gauchan^*, David Crockett^*

Oncology Research, Vol.26, No.3, pp. 515-518, 2018, DOI:10.3727/096504017X15128550060375

Abstract Solid tumors involving glandular organs express mucin glycoprotein that is eventually shed into the circulation. As a result, these proteins can easily be measured in the serum and be used as potential tumor markers. The most commonly used tumor markers for breast cancer are CA27-29 and CA15-3, which both measure the glycoprotein product of the mucin-1 (MUC1) gene. CA27-29 has been approved by the US Food and Drug Administration for monitoring disease activity in breast cancer patients. Most oncology clinical practice guidelines do not recommend the use of tumor markers for routine surveillance of early… More >

Faina Linkov¹, Yian Gu⁴, Alan A. Arslan^2,3,4, Mengling Liu⁴, Roy E. Shore^2,5, Lyudmila Velikokhatnaya¹, Karen L. Koenig^2,4, Paolo Toniolo³, Adele Marrangoni¹, Zoya Yurkovetsky¹, Anne Zeleniuch-Jacquotte^2,4, Anna E. Lokshin^1,6,7

European Cytokine Network, Vol.20, No.1, pp. 21-26, 2009, DOI:10.1684/ecn.2009.0146

Abstract There is a growing interest in the role that cancer biomarkers, metastasis-related molecules, and chemokines may play in the development and progression of various cancers. However, few studies have addressed the reliability of such biomarkers in healthy individuals over time. The objective of this study was to investigate the temporal reliability of multiple proteins in serum samples from healthy women who donated blood over successive years. Thirty five, postmenopausal women with two, repeated annual visits, and thirty, premenopausal women with three, repeated annual visits were randomly selected among eligible subjects from an existing, prospective cohort.… More >

Robert K. Nam¹, Ants Toi², Laurence H. Klotz¹, John Trachtenberg³, Michael A. S. Jewett³, Andrew Loblaw⁴, Greg R. Pond¹, Marjan Emami¹, Linda Sugar⁵, Joan Sweet⁶, Steven A. Narod⁷

Canadian Journal of Urology, Vol.13, Suppl.2, pp. 2-10, 2006

Abstract Background: There is a large amount of confusion in interpreting prostate specific antigen (PSA) values for prostate cancer. More precise risk assessments for prostate cancer detection are needed for men faced with an abnormal PSA.
Methods: We studied a sample of 2637 men who underwent a prostate biopsy for an abnormal digital rectal exam (DRE) or PSA. Using factors including age, ethnicity, family history of prostate cancer, previous negative biopsy, presence of voiding symptoms, prostate volume, DRE and PSA, we constructed nomograms to predict the probability of prostate cancer at biopsy.
Results: Of the 2637 men, 1282 men… More >

Yves Fradet

Canadian Journal of Urology, Vol.9, No.3, pp. 1544-1550, 2002

Abstract Superficial bladder tumors are by far the most common form of bladder cancer managed by practicing urologists. Indeed up to 75% of initial tumors fall in this category and because of the high recurrence rate, superficial tumors represent over 90% of tumor events being treated. New diagnostic methods have been developed to improve the sensitivity of tumor detection of both cystoscopy and urinary cytology. Risk stratification of patients based on simple clinical parameters provides new opportunities for adapting monitoring strategies as well as providing a rationale for the use of intravesical chemotherapy and immunotherapy. Finally, More >